ライフサイエンスコーパス: PCV13

1 PCV13 has reduced serotype 19A carriage among vaccinated

2 PCV13 introduction was associated with declines in the r

3 PCV13 serotypes made up 88% (7/8) of S. pneumoniae menin

4 PCV13 serotypes were responsible for 20.1% (n = 4033), w

5 PCV13 use in children had a moderate impact on reducing

6 PCV13 use is probably cost-effective in all six UN regio

7 PCV13-immunized children aged 13-48 months, N = 988, wer

8 12, and 24 months after vaccination in 1006 PCV13 recipients and 1005 controls with 3 age-stratified

9 CV10) and pneumococcal conjugate vaccine 13 (PCV13), are used in childhood immunization programs worl

10 As compared to children receiving 2p+1b PCV13 dosing, those receiving 1p+1b and 2p+0b schedules

11 As compared to children receiving 2p+1b PCV13 dosing, those receiving 1p+1b and 2p+0b schedules

12 A 2p+1b PCV13 series conferred 40% (4-67%) and 62% (33-83%) prot

13 A 2p+1b PCV13 series conferred 40% (95% CI, 4-67%) and 62% (95%

14 and 2018, 3.6-7.1 years after Malawi's 2011 PCV13 introduction.

15 Compared to 2011-2013, PCV13-serotype incidence was significantly lower among a

16 n against PCV7-targeted serotypes than the 6 PCV13-only serotypes.

17 s is the first report of a LAMP method for a PCV13 serotype-specific identification assay, which coul

18 At ages 12-35 months, a PCV13 schedule containing two primary doses and one boos

19 , compared to PCV7 serotypes, the additional PCV13 serotypes are more likely to cause bacteremic LRTI

20 among children age <2 years before and after PCV13 introduction, accounting for the dependence betwee

21 CV13) and their mothers 5 years (CSS3) after PCV13 introduction.

22 D incidence among U.S. adults declined after PCV13 introduction in children.

23 IPD incidence among US adults declined after PCV13 introduction in children.

24 sed during the PCV7 years and declined after PCV13 introduction.

25 ignificantly lower IPD rates were seen after PCV13 introduction in adults aged <65 years (IRR 0.78, 9

26 Five years after PCV13 introduction, we show both direct (infants) and in

27 incidence (cases per 100 000) 4 years after PCV13's introduction (2017) to average pre-PCV13 inciden

28 .8-100.0%) and 91.4% (-191.4-100.0%) against PCV13-serotype and PCV7-serotype CAAP.

29 veness of two or more doses of PCV13 against PCV13-serotype invasive pneumococcal disease was 85% (95

30 Protection against PCV13-serotype and PCV7-serotype CAAP was 67.0% (-424.3-

31 ce interval [CI], 32-67%) protection against PCV13-serotype colonization at ages <=12 months; 1 prima

32 erred 53% (95%CI: 32-67%) protection against PCV13-serotype colonization at ages <=12m; one primary-s

33 and 62% (95% CI, 33-83%) protection against PCV13-serotype colonization at ages 13-24 months and 25-

34 (4-67%) and 62% (33-83%) protection against PCV13-serotype colonization at ages 13-24m and 25-59m, r

35 n immunocompetent adults >/=65 years of age, PCV13 elicits significant increases in OPA titers and Ig

36 with PCV7-immunized children, carriage among PCV13-immunized children was significantly lower for ser

37 e sequential introduction of PCV7 (2006) and PCV13 (2011) in the Norwegian childhood vaccination prog

38 7-valent PCV (PCV7; introduced in 2006) and PCV13 (introduced in 2010).

39 ted with the introduction of PCV7 (2007) and PCV13 (2010) while controlling for serotype-specific epi

40 e nationwide introduction of PCV7 (2009) and PCV13 (2011).

41 conjugate vaccine (PCV7)-era (2006-2010) and PCV13-era (2011-2014) birth cohorts, accounting for risk

42 cine (PCV)7 in June 2008, PCV10 in 2011, and PCV13 in 2014.

43 n with PCV7 (IRR 0.45, 95% CI 0.38-0.54) and PCV13 serotypes (IRR 0.60, 95% CI 0.54-0.68).

44 PCV10 and PCV13 are similarly highly immunogenic when used in 2 +

45 Serotype 6A declined in PCV10 and PCV13 counties, whereas serotype 19A increased in PCV10

46 ttle data on the immunogenicity of PCV10 and PCV13 in the same high-risk population.

47 PCV10 and PCV13 were studied head-to-head in a randomized controll

48 pare vaccination responses between PCV10 and PCV13, and to evaluate different schedules of PCV10.

49 the introduction of PCV13 alone or PCV10 and PCV13, the pooled IRR was 0.53 (95% CI 0.43-0.65) for in

50 munogenicity and reactogenicity of PCV10 and PCV13.

51 and four use the ten-valent PCV (PCV10) and PCV13.

52 After 3 vaccine doses, PCV7 and PCV13 failure rates were 0.19/100000 (95% confidence int

53 Following the introduction of PCV7 and PCV13 in children, the net impact of serotype replacemen

54 In this study, the impact of PCV7 and PCV13 on MR-IPD was prospectively assessed.

55 PCV7 and PCV13 were implemented in Israel in July 2009 and Novemb

56 of pneumococcal conjugate vaccine (PCV7 and PCV13).

57 >=4 episodes in 12 months) between PCV7- and PCV13-era birth cohorts.

58 -analysis of observational studies to assess PCV13 vaccine effectiveness (VE) for serotype 3 IPD in c

59 In Indigenous people, baseline PCV13 non-PCV7 IPD incidence was 3-fold higher, amplifie

60 In Indigenous people, baseline PCV13-non7v IPD incidence was 3-fold higher, amplified b

61 ing (CSS1-3), and after the trial but before PCV13 (CSS4).

62 ose from 2 previous surveys conducted before PCV13 introduction (CSS1) and 1 year later (CSS2).

63 evidence was found of an association between PCV13 vaccination and Kawasaki disease onset in the 4 we

64 s compared to infants born at term, for both PCV13 and non-PCV13 serotypes.

65 The overall reductions of IPD cases by PCV13 serotypes in children and adults were 88% and 59%

66 mpetent adults seems to control IPD cases by PCV13 serotypes including serotype 3.

67 to 25% and 11% respectively the IPD cases by PCV13 serotypes, showing a decrease of serotype 3 when P

68 In Burkina Faso, meningitis caused by PCV13 serotypes continues to decrease, especially among

69 Pneumococcal meningitis caused by PCV13 serotypes decreased from 100% in 2011 to 50% in 20

70 nvasive pneumococcal disease (IPD) caused by PCV13-targeted serotypes still represents an important p

71 setting of an established national childhood PCV13 vaccination programme, PPV23 vaccination of clinic

72 Incidence-rate ratios (IRRs) comparing PCV13 (2014-2017) with pre-PCV (2004-2008) periods were

73 1 (group C), or two-dose schedule (group D); PCV13 in a 2 + 1 schedule (group E); or no infant PCV (c

74 ethodologies and high quality support direct PCV13 protection against serotype 3 IPD in children.

75 in group C (PCV10) and 232 (92%) in group E (PCV13) completed the primary vaccination series and had

76 seroprotective antibody levels against each PCV13 pneumococcal serotype at D301.

77 een November 2010 and September 2011 ("early PCV13").

78 ) in the late PCV13 period than in the early PCV13 period.

79 for all adults >=65 years old, we evaluated PCV13 impact on invasive pneumococcal disease (IPD) amon

80 We evaluated PCV13 indirect effects on invasive pneumococcal disease

81 Following PCV13 introduction into the Cambodian immunization sched

82 Following PCV13 introduction, dual macrolide-resistant IPD decreas

83 of Kawasaki disease in the 28 days following PCV13 vaccination.

84 ger study of Kawasaki disease risk following PCV13 vaccination in the claims-based Sentinel/Postlicen

85 mmunocompromising conditions (indication for PCV13 use), 57% (95% CI, -62% to -52%) in immunocompeten

86 ocompromising conditions (IC, indication for PCV13 use), 57% (95%CI:-62, -52) in immunocompetent adul

87 ildren 5 to 10 years old (age-ineligible for PCV13), and HIV-infected adults (18 to 40 years old) on

88 l ages, the drop in incidence was larger for PCV13 serotypes excluding serotype 1 (79%; 95% CI, 72%-8

89 We estimate that global PCV13 use could prevent 0.399 million child deaths (95%

90 Estimates suggested greater PCV13-conferred protection against PCV7-targeted serotyp

91 Estimates suggested greater PCV13-conferred protection against PCV7-targeted serotyp

92 14 and 2007-2008, by age and serotype group (PCV13, PPSV23-unique, or nonvaccine types [NVTs]), among

93 14 and 2007-2008, by age and serotype group (PCV13, PPSV23-unique, or types in neither vaccine [NVT])

94 tchemotherapy vaccination with DTaP-IPV-Hib, PCV13, and PPV23 was immunogenic and well tolerated.

95 es in pediatric meningitis hospitalizations, PCV13-type pneumococcal meningitis, and severe and moder

96 The decrease in PCV13 VT that has occurred since the introduction of PCV

97 oss-protection with 6A, which is included in PCV13.

98 r the 13 capsular types that are included in PCV13: 1, 3, 4, 5, 6 A, 6B, 7 F, 9 V, 14, 18 C, 19 A, 19

99 e 6C increased in PCV10 counties, but not in PCV13 counties, suggesting cross-protection with 6A, whi

100 n NVTs, excluding 6C, was more pronounced in PCV13 counties.

101 Similar reductions in PCV13-type IPD in those with and without PCV13 indicatio

102 Similar reductions in PCV13-type IPD in those with and without PCV13 indicatio

103 gs show that for nine of the 13 serotypes in PCV13, post-booster responses in infants primed with a s

104 Any changes to the infant PCV13 immunization schedule may disproportionally affect

105 The initial PCV13 uptake period (October 2013-September 2014) was co

106 Low-income countries that introduce PCV13 with reasonable coverage can expect modest reducti

107 ) was calculated for age-specific total IPD, PCV13 non-7-valent PCV (PCV7) serotypes, and PnCAP by In

108 ) was calculated for age-specific total IPD, PCV13-non7v serotypes and PnCAP by Indigenous status.

109 between February 2014 and August 2015 ("late PCV13"), and had nasopharyngeal pneumococcal carriage co

110 3 (IRR, 2.3 [95% CI, .86-6.15]) in the late PCV13 period than in the early PCV13 period.

111 A (n = 30 [28.6%]) were responsible for most PCV13 failures.

112 From 2013 to 2014, non-PCV13 serotypes accounted for 80% of IPD.

113 From 2013-2014, non-PCV13 serotypes accounted for nearly 80% of IPD.

114 erotypes) or non-vaccine-type GPSC (>50% non-PCV13 serotypes) on the basis of its initial serotype co

115 infants born at term, for both PCV13 and non-PCV13 serotypes.

116 serotyped isolates, most were caused by non-PCV13 serotypes (369 cases, 71.4%), with 85 cases (16.4%

117 invasive pneumococcal disease caused by non-PCV13 serotypes increased, which suggests serotype repla

118 Among the emerging non-PCV13 types (NVTs), those known to have the highest dise

119 ential reasons for the rapid increase in non-PCV13 (non-vaccine serotype [NVT]) IPD cases since 2014.

120 However, the concurrent decline in non-PCV13 serotypes and short pre-PCV13 observation period c

121 e 1 (52%; 95% CI, 44%-59%); incidence of non-PCV13 serotypes also declined (53%; 95% CI, 37%-65%).

122 ped countries have seen the emergence of non-PCV13 serotypes.

123 3 carriage or disease, and emergence of non-PCV13-serotype disease.

124 otypes (68 [52-81] years), and remaining non-PCV13 serotypes (70 [53-82] years).

125 jugate vaccine (PCV13) and the remaining non-PCV13 serotypes.

126 The non-PCV13 incidence increased by 4-10%, mostly in individual

127 IPD due to non-PCV13 serotypes increased by 30% compared with 76% for n

128 stimate the relative risk of PCV13-type, non-PCV13-type, and overall IPD in premature infants compare

129 tional 11 serotypes covered by PPV23 but not PCV13.

130 vi, the Vaccine Alliance, account for 83% of PCV13-preventable deaths but only 18% of global vaccinat

131 y jurisdictions; a comparative assessment of PCV13's impact was missing.

132 e risk of Kawasaki disease within 28 days of PCV13 vaccination with the historical risk after 7-valen

133 later by saline placebo or a single dose of PCV13 followed 1 month later by 23-valent polysaccharide

134 o study groups and received a single dose of PCV13: Group 1 - maintenance chemotherapy; Group 2 - end

135 o study groups and received a single dose of PCV13: group 1, maintenance chemotherapy; group 2, end o

136 With more than 6 million doses of PCV13 administered, no evidence was found of an associat

137 The effectiveness of two or more doses of PCV13 against PCV13-serotype invasive pneumococcal disea

138 imate of the effectiveness of three doses of PCV13 against radiological pneumonia was an adjusted odd

139 At the same timepoint, two doses of PCV13 were non-inferior to three doses of PCV10 for nine

140 observation period complicate evaluation of PCV13's impact.

141 prospectively assessed the immunogenicity of PCV13 followed by PPSV23 in IBD patients by measuring se

142 The impact of PCV13 on a number of clinical aspects of pneumococcal pn

143 We evaluated the impact of PCV13 on pediatric pneumonia and meningitis.

144 We evaluated the impact of PCV13 on pneumococcal meningitis.

145 We found no impact of PCV13 on serotype 3 carriage or disease, and emergence o

146 4 years after the introduction of PCV13 alone or PCV10 and PCV13, the pooled IRR was 0.53

147 that has occurred since the introduction of PCV13 appears to have plateaued.

148 rect effects before the 2014 introduction of PCV13 for all adults >=65 years old, we evaluated PCV13

149 se (IPD) in adults after the introduction of PCV13 in childhood immunization programs.

150 Introduction of PCV13 or PPV23 in the adult calendar of certain Spanish

151 f MDR serotype 35B after the introduction of PCV13 was directly associated with the emergence of ST15

152 periods before and after the introduction of PCV13.

153 The prevalence of PCV13 NVT increased between CSS0 and CSS5 for children <

154 We estimated the prevalence of PCV13 VT and NVT by age and compared these to earlier su

155 The prevalence of PCV13 VT carriage decreased during the 10 years between

156 Hospitalization rates of PCV13 serotype pneumonia decreased from 47.2 to 15.7 per

157 the incremental cost-effectiveness ratio of PCV13 introduction by integrating two models: an ecologi

158 nfants, and to estimate the relative risk of PCV13-type, non-PCV13-type, and overall IPD in premature

159 infants given a reduced priming schedule of PCV13 (ie, a 1 + 1 schedule) versus the current 2 + 1 sc

160 hough the sequential vaccination schedule of PCV13 followed by PPSV23 is safe, immunogenic, and thus

161 essed whether the two-dose primary series of PCV13 (group E) was non-inferior at the 10% level to a t

162 Use of PCV13 in children has shown a clear impact in pneumococc

163 n, where the 21 counties use either PCV10 or PCV13 (introduced 2009-2010).

164 ich 262 infants received 3 doses of PCV10 or PCV13 at 1, 2, and 3 months of age.

165 Infant vaccination with 3 doses of PCV10 or PCV13 is safe and immunogenic in a highly endemic settin

166 One month after the third dose of PCV10 or PCV13, >80% of infants had IgG concentrations >=0.35ug/m

167 of children vaccinated with either PCV10 or PCV13.

168 were similar after vaccination with PCV20 or PCV13; no serious vaccine-related AEs were reported.

169 Sentinel/PRISM data-providing organizations, PCV13 vaccinations were identified by means of current p

170 all ages were serotype 1 and 12% were other PCV13 serotypes.

171 s of serotypes present in the 13-valent PCV (PCV13) and 7 new serotypes (8, 10A, 11A, 12F, 15B, 22F,

172 fants who received 3 doses of 13-valent PCV (PCV13) and their mothers 5 years (CSS3) after PCV13 intr

173 al serotypes contained in the 13-valent PCV (PCV13) but not in PCV7.

174 cific 7-valent PCV (PCV7) and 13-valent PCV (PCV13) effectiveness against vaccine-serotype colonizati

175 PD outbreak in Israel, in the 13-valent PCV (PCV13) era, with focus on Sp2 population structure and e

176 clinical presentations after 13-valent PCV (PCV13) implementation.

177 (PCV7) from 2005, replaced by 13-valent PCV (PCV13) in 2011, uniquely among high-income countries giv

178 children in 2005, changing to 13-valent PCV (PCV13) in 2011.

179 healthy carriers 2 years from 13-valent PCV (PCV13) introduction and 1 year after rollout in northern

180 in countries with established 13-valent PCV (PCV13) programs.

181 ectiveness of introduction of 13-valent PCV (PCV13) vaccination globally.

182 ), ten-valent PCV (PCV10) and 13-valent PCV (PCV13).

183 e as vaccine-type GPSC (>=50% 13-valent PCV [PCV13] serotypes) or non-vaccine-type GPSC (>50% non-PCV

184 ups at the 10% level for any serotype (PCV10-PCV13 risk difference -2.1% [95% CI -4.8 to -0.1] for se

185 7-valent PCV (PCV7)/PCV13 vaccines were introduced in July 2009 and November

186 against the seven serotypes shared by PCV7, PCV13, and PSV23.

187 ters against the 7 serotypes shared by PCV7, PCV13, and PSV23.

188 PCV7/PCV13 implementation resulted in a marked decline in CAA

189 PCV7/PCV13 implementation resulted in a marked decline in CAA

190 PCV7/PCV13 were implemented in Israel in July 2009/November 2

191 CAAP rates markedly declined following PCV7/PCV13 introduction worldwide.

192 by PCVs.Pneumococcal conjugate vaccine (PCV7/PCV13) implementation resulted in significant declines i

193 at the time of 7- and 13-valent PCVs (PCV7; PCV13) implementation.

194 rgely due to indirect effects from pediatric PCV13 use rather than direct use among adults.

195 rgely due to indirect effects from pediatric PCV13 use rather than direct use among adults.

196 d for 2007-2010 (pre-PCV13), 2011-2012 (peri-PCV13), and 2013-2015 (post-PCV13).

197 The pooled PCV13 VE against serotype 3 IPD from the random-effects

198 from 53.6 to 23.3 per 100000 admissions post PCV13 (P < .0001).

199 from 47.2 to 15.7 per 100000 admissions post PCV13.

200 15 years post PCV and 5 years post PCV13, direct and indirect impact on IPD and PnCAP diffe

201 Post-PCV13 declines in serotype 19A IPD in persons aged <2 ye

202 Post-PCV13 introduction, meningitis hospitalization decreased

203 IPD declined from 11.8 pre-PCV7 to 7.1 post-PCV13 (IRR 0.61, 95% CI 0.59-0.63) but for PnCAP decline

204 IPD declined from 11.8 pre-PCV7 to 7.1 post-PCV13 (IRR, 0.61 [95% confidence interval {CI}, .59-.63]

205 2011-2012 (peri-PCV13), and 2013-2015 (post-PCV13).

206 pre-PCV13 (January 2010-June 2012) and post-PCV13 (July 2013-December 2016) using a negative binomia

207 05-2007), pre-PCV13 (2008-mid 2011) and post-PCV13 (mid 2011-2016) periods was used to calculate inci

208 007), pre-PCV13 (2008 to mid-2011), and post-PCV13 (mid-2011 to 2016) periods was used to calculate i

209 erparts) increased during the peri- and post-PCV13 periods compared with the pre-PCV13 period.

210 We also evaluated post-PCV13 changes in serotype distribution among children wi

211 declines in pneumonia hospitalizations post-PCV13 introduction.

212 the numbers of S. pneumoniae meningitis post-PCV13 is encouraging and should continue to be monitored

213 ant reduction in pneumonia was observed post-PCV13 (-3.8%, 95% confidence interval [CI] -1.5 to -5.9%

214 t change in annual decline was observed post-PCV13.

215 and 7% (95% CI, -11, -2), respectively, post-PCV13 introduction.

216 From pre- to post-PCV13 period, IPD rates declined 5%-48% and ACHP rates d

217 vere and moderate ARI outpatient visits post-PCV13 introduction.

218 ause pneumonia hospitalizations 2 years post-PCV13 introduction in infants; the same trend was not me

219 vaccine (PCV) introduction and 5 years post-PCV13, direct and indirect impact on invasive pneumococc

220 Fifteen years post-PCV and 5 years post-PCV13, direct and indirect impact on IPD and PnCAP diffe

221 Postlicensure PCV13 effectiveness studies against serotype 3 invasive

222 CV7 (2002-2004), early PCV7 (2005-2007), pre-PCV13 (2008 to mid-2011), and post-PCV13 (mid-2011 to 20

223 CV7 (2002-2004), early-PCV7 (2005-2007), pre-PCV13 (2008-mid 2011) and post-PCV13 (mid 2011-2016) per

224 unterparts were estimated for 2007-2010 (pre-PCV13), 2011-2012 (peri-PCV13), and 2013-2015 (post-PCV1

225 r PCV13's introduction (2017) to average pre-PCV13 incidence (2011-2013).

226 children aged <5 years steadily declined pre-PCV13; no significant change in annual decline was obser

227 5 years at Harare Central Hospital (HCH) pre-PCV13 (January 2010-June 2012) and post-PCV13 (July 2013

228 decline in non-PCV13 serotypes and short pre-PCV13 observation period complicate evaluation of PCV13'

229 and post-PCV13 periods compared with the pre-PCV13 period.

230 udies and 2 conference posters that provided PCV13 VE estimates stratified by serotype.

231 ants were randomly assigned (1:1) to receive PCV13 at 2, 4, and 12 months (2 + 1 schedule) or 3 and 1

232 Receiving 2 primary-series PCV13 doses conferred 53% (95% confidence interval [CI],

233 Two primary-series PCV13 doses conferred 53% (95%CI: 32-67%) protection aga

234 duction of a vaccine targeting 13 serotypes (PCV13) in 2010 has led to concern that this scenario wil

235 s is the first widespread Sp2 outbreak since PCV13 introduction worldwide, caused by the emerging ST-

236 against PCV7-targeted serotypes than the six PCV13-only serotypes.

237 to assess the long-term impact of sustained PCV13 use and to monitor how pneumococcus is causing dis

238 Routine surveillance showed that PCV13 vaccination is effective in preventing pneumococca

239 The PCV13 incidence decreased by 5-12% across groups.

240 mpared hospitalizations before and after the PCV13 introduction, accounting for seasonality.

241 trends of meningitis and pneumonia after the PCV13 introduction.

242 erm infants during a 4-year period after the PCV13 program was established.

243 riod (May 12, 2008, to May 11, 2010) and the PCV13 period (Jan 1, 2014, to Dec 31, 2015).

244 2017 and incidence rate ratios comparing the PCV13 (2014-2017) with the pre-PCV (2004-2008) periods.

245 In the PCV13 era, the RR for IPD was highest (significant) and

246 of 249 vs 65 [11%] of 575, p=0.0031) in the PCV13 period compared with the pre-PCV period.

247 The five most prevalent serotypes in the PCV13 period varied between countries, with only serotyp

248 erotype invasive pneumococcal disease in the PCV13 period.

249 .0%) protection against CAAP attributable to PCV13-serotype pneumococci, and 92.3% (-0.9-100.0%) prot

250 n 2001 and all children in 2005, changing to PCV13 in 2011.

251 cases, 71.4%), with 85 cases (16.4%) due to PCV13 serotypes.

252 here is residual carriage and disease due to PCV13-covered serotypes.

253 The transition from PCV7 to PCV13 was associated with a decline of OM among children

254 We determined the immune responses to PCV13 before and at 1, 12, and 24 months after vaccinati

255 The switch to PCV13 was associated with large declines in pneumococcal

256 At ages 4-11 months, two PCV13 doses provided 98.9% (-309.8-100.0%) and 91.4% (-1

257 etent adults comparing Spanish regions using PCV13 vs regions using PPV23 vaccine was also analyzed f

258 se 13-valent pneumococcal conjugate vaccine (PCV13) alone and four use the ten-valent PCV (PCV10) and

259 he 13-valent pneumococcal conjugate vaccine (PCV13) and the remaining non-PCV13 serotypes.

260 nd 13-valent pneumococcal conjugate vaccine (PCV13) concurrently, followed by 23-valent pneumococcal

261 of 13-valent pneumococcal conjugate vaccine (PCV13) during and after chemotherapy.

262 he 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide

263 he 13-valent pneumococcal conjugate vaccine (PCV13) from the existing 2+1 schedule (2, 4, 12 months).

264 ed 13-valent pneumococcal conjugate vaccine (PCV13) in 2012 using a 3-dose infant schedule with no bo

265 he 13-valent pneumococcal conjugate vaccine (PCV13) in January 2015 using a 3 + 0 dosing schedule and

266 a 13-valent pneumococcal conjugate vaccine (PCV13) in October 2013, given at 6, 10, and 14 weeks of

267 nd 13-valent pneumococcal conjugate vaccine (PCV13) in the childhood vaccination program in Denmark.

268 ed 13-valent pneumococcal conjugate vaccine (PCV13) into the routine childhood immunization program,

269 of 13-valent pneumococcal conjugate vaccine (PCV13) introduction on the occurrence of first and subse

270 he 13-valent pneumococcal conjugate vaccine (PCV13) is the only licensed PCV with serotype 3 polysacc

271 a 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7 in many jurisdictions; a comparativ

272 on-13-valent pneumococcal conjugate vaccine (PCV13) serotype pneumonia (n = 417 cases, 43.7% vaccinat

273 he 13-valent pneumococcal conjugate vaccine (PCV13) was designed to include disease-causing serotypes

274 he 13-valent pneumococcal conjugate vaccine (PCV13) was initially introduced in the national immuniza

275 luded in the pneumococcal conjugate vaccine (PCV13) was recently reported as a useful diagnostic tool

276 he 13-valent pneumococcal conjugate vaccine (PCV13) were introduced in 2008 and 2014, respectively.

277 or 13-valent pneumococcal conjugate vaccine (PCV13), comparing the risk of Kawasaki disease within 28

278 he 13-valent pneumococcal conjugate vaccine (PCV13), there is residual carriage and disease due to PC

279 The 13-valent pneumococcal vaccine (PCV13) was introduced for U.S. children in 2010, and for

280 The 13-valent pneumococcal vaccine (PCV13) was introduced for US children in 2010 and for im

281 he 13-valent pneumococcal conjugate vaccine [PCV13] as part of the Expanded Program on Immunization [

282 types, showing a decrease of serotype 3 when PCV13 was used.

283 starting from children 2-5 years of age with PCV13 have been highly effective in reducing the inciden

284 South Africa replaced PCV7 with PCV13 in 2011 using a 2 + 1 schedule.

285 evaluated the impact of replacing PCV7 with PCV13 on disease burden in adults and identified age/ris

286 PCV10 and 81% (95% CI 72-88) vaccinated with PCV13 were pneumococcal carriers (P = .023), whereas no

287 Vaccination with PCV13 in immunocompetent adults seems to control IPD cas

288 in PCV13-type IPD in those with and without PCV13 indications suggest observed benefits are largely

289 in PCV13-type IPD in those with and without PCV13 indications suggest that observed benefits are lar

290 disease (IPD) among adults with and without PCV13 indications.

291 accine [NVT]), among adults with and without PCV13 indications.

292 disease (IPD) among adults with and without PCV13 indications.

293 types [NVTs]), among adults with and without PCV13 indications.

294 did not change among adults with or without PCV13 indications.

295 did not change among adults with or without PCV13 indications.

296 s lower than serotype 9N (67 [53-80] years), PCV13 serotypes (68 [52-81] years), and remaining non-PC

297 Among adults 19-64 years, PCV13-type IPD declined 57% (95% confidence interval [CI

298 Among adults 19-64 years, PCV13-type IPD declined 57% (95%CI:-68,-43) in adults wi

299 Among adults aged >=65 years, PCV13-type IPD decreased 68% (95% CI, -76% to -60%) in t

300 Among adults >=65 years, PCV13-type IPD decreased 68% (95%CI:-76,-60) in those wi